Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
about
Clinical and economic studies of eptifibatide in coronary stentingAcute profound thrombocytopenia secondary to local abciximab infusion.Orofacial adverse effects of biological agents.Progress in the research of GPIIb/IIIa antagonists.Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.A Short Half-Life αβ₃ Antagonist ANTP266 Reduces Thrombus Formation
P2860
Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimal use of platelet glycop ...... aneous coronary interventions.
@en
Optimal use of platelet glycop ...... aneous coronary interventions.
@nl
type
label
Optimal use of platelet glycop ...... aneous coronary interventions.
@en
Optimal use of platelet glycop ...... aneous coronary interventions.
@nl
prefLabel
Optimal use of platelet glycop ...... aneous coronary interventions.
@en
Optimal use of platelet glycop ...... aneous coronary interventions.
@nl
P2093
P2860
P1433
P1476
Optimal use of platelet glycop ...... aneous coronary interventions.
@en
P2093
Ankit A Patel
George A Stouffer
H Benjamin Starnes
P2860
P304
P356
10.2165/11595010-000000000-00000
P577
2011-10-01T00:00:00Z
P6179
1046306801